CSN Login
Members Online: 15

You are here

Member Resource Library

Hand-foot syndrome help

Type: 
Article
Description: 

Colon and breast cancer patients who take Xeloda know the side effect Hand-Foot Syndrome (HFS) or Palmar-Plantar Erythrodysesthesia (PPE). A study at a university in Turkey looked at the use of henna in treating PPE. This webpage tells you how to use it. Reference to the Turkish study is given.

Source: 
Webpage
Author/Speaker/Performer: 
Monique Doyle Spencer

Visions for Cancer Recovery

Type: 
Article
Description: 

From the moment of diagnosis, take advantage of this remarkable Integrative Visual Therapy program that is intended as a daily companion to traditional cancer treatments.

Experience a series of deep-relaxation and stress-reduction techniques, before taking a revolutionary glimpse inside the body where scientifically-based animation represents the process of apoptosis, or cancer cell elimination.

Source: 
Integral Visions
Contact information: 
phone: 952 922 8291 mary@integral-visions.com
Author/Speaker/Performer: 
E’Louise Ondash, RN
gdpawel's picture

Why Community Oncology Can Benefit From Cell Function Analysis

Type: 
Article
Description: 

As increasing numbers and types of anti-cancer drugs are developed, oncologists become increasingly likely to misuse them in their practice. There is seldom a "standard" therapy which has been proven to be superior to any other therapy. When all studies are compared by meta-analysis, there is no difference. What may work for one, may not work for another.

Cancer chemotherapy could save more lives if pre-testing were incorporated into clinical medicine. The respected cancer journals are publishing articles that identify safer and more effective treatment regimens, yet few community oncologists are incorporating these synergistic methods into their clinical practice. Cancer patients suffer through chemotherapy sessions that do not integrate all possibilities.

Distinguishing between patients with a "high" or "low" risk for early recurrence after surgical resection and identifying those who may respond to correct adjuvant therapy have been topics of great interest for many years. Both genetic and functional assay analyses share a role in the development of "personalized" patient care.

A genomic test can help to find out if a cancer patient will likely have a recurrence after surgery. If a recurrence isn't likely, they don't need chemotherapy. Genetic tests have been developed for breast and lung cancers. Hopefully, there will be more tests for other types of cancer to guide physicians as to which "high" risk patient will likely have a recurrence if treated with surgery alone (1).

If the test finds a patient to be at "high" risk, it is impossible to design a single chemotherapy protocol that is effective against all types of cancer. The oncologist might need to administer several chemotherapy drugs at varying doses because tumor cells express survival factors with a wide degree of individual cell variability. A cell culture assay test, using a cell-death endpoint, can help see what treatments will not have the best opportunity of being successful (resistant) and identify drugs that have the best opportunity of being successful (sensitive).

The current clinical applications of in vitro chemosensitivity testing is ever more important with the influx of new "targeted" therapies. Given the technical and conceptual advantages of "functional profiling" of cell culture assays together with their performance and the modest efficacy for therapy prediction on analysis of genome expression, there is reason for renewed interest in these assays for optimized use of medical treatment of malignant disease (2).

The chemotherapy regimen chosen by most community oncologists is based on the type of cancer being treated. However, there are factors other than the type of cancer that can be used to determine the ideal chemotherapy drugs that should be used to treat an individual patient.

It is highly desirable to know what drugs are effective against particular cancer cells before these toxic agents are systemically administered. Pre-testing on "fresh" specimens of cancer cells to determine the optimal combination of chemotherapy drugs could be highly beneficial.

Following the collection of "fresh" cancer cells obtained at the time of biopsy or surgery, a cell culture assay is performed on the tumor sample to measure drug activity (sensitivity and resistance). This will pinpoint which drug(s) are most effective. The treatment program developed through this approach is known as assay-directed therapy.

At present, medical oncologists prescribe chemotherapy according to "fixed" schedules. These schedules are standardized drug regimens that correspond to specific cancers by type or diagnosis. These regimens, developed over many years of clinical trials, assign patients to the drugs which previously worked for some percentage of patients.

However, cancer is a disease whose hallmark is heterogeneity. It is well known that drugs which work for one patient often don't work for another and patients who fail to respond to first line chemotherapy with one regimen often respond to second or third line therapy with alternative drugs. Why not identify the right regimen before ever exposing a patient to a single course of chemotherapy? A failed attempt at chemotherapy is detrimental to the physical and emotional well being of patients, is financially burdensome, and may promote the onset of clinically acquired multi-drug resistance.

A "fresh" sample tumor can be obtained from surgery or biopsy (Tru-cut needle biopsies). Tissue, blood, bone marrow, and ascites and pleural effusions are possibilities, providing tumor cells are present, and only live cells should be used. At least one gram of fresh biopsy tissue is needed to perfom the tests, and a special kit is obtained in advance from the lab. Arrangements are made with the surgeon and/or pathologist for preparation and sending of the specimen.

Upgrading clinical therapy by using drug sensitivity assays measuring "cell death" of three dimensional microclusters of live "fresh" tumor cells can improve the conventional situation by allowing more drugs to be considered. The key to improving drug sensitivity tests is related to the number and types of drugs tested. The more anti-cancer drug types there are in the selective arsenal, the more likely the system is to prove beneficial.

In order to acquire sufficient data, tumors should be tested with at least two assay endpoints, and most often three, for sensitivity tests in any one patient. On average, up to twenty drugs and combinations at two concentrations in three different assay systems, is an effective way to avoid false-positive or false-negative data.

Assays based on "cell-death" occur in the entire population of tumor cells, as opposed to only in a small fraction of the tumor cells occurring in "cell-growth" assays. Drug "sensitivity" testing is merely a point a little farther along on the very same continuum upon which "resistance" testing resides, which has been proven to be accurate and reliable, as reported in numerous peer-reviewed publications.

Good review papers exist on cell culture assays and are increasingly appreciated and applied in the private sector by European clinicians and scientists. The literature on these assays have not been understood by many NCI investigators and by NCI-funded university investigators, because their knowledge has been based largely on an assay technique (cell-growth) that hasn't been used in most private labs for over fifteen years (3).

Data show conclusively that patients benefit both in terms of response and survival from drugs and drug combinations found to be "active" in the assay even after treatment failure with several other drugs, many of which are in the same class, and even with combinations of drugs found to have low or no activity as single agents but which are found in the assay to produce a synergistic and not merely an additive anti-tumor effect.

Patients receiving a drug that tested "sensitive" were 1.44 times [i.e. 44%] more likely to respond compared to all patients treated in studies, while patients testing "resistant" were 0.23 as likely to respond as all patients. Patients receiving treatment with drugs testing "sensitive" enjoyed a 6-fold advantage (1.44/0.23 = 6.23) over patients treated with drugs testing "resistant."

This data includes both patients with solid tumors (e.g., breast cancer, lung cancer) and hematological (blood system) tumors (e.g. leukemia, lymphoma). In the case of solid tumors only, the advantage to receiving sensitive versus resistant drugs was 9.3 fold. In the case of breast cancer, it was more than 10-fold. Furthermore, patients receiving "sensitive" drugs were shown in many studies to enjoy significantly longer durations of survival than patients treated with "resistant" drugs.

Patients treated with a "positive" (sensitive) drug would respond 79.1% of the time, while patients treated with a "negative" (resistant) drug would respond only 12.6% of the time. Once again, there would be a huge advantage to the patient to receive a "positive/sensitive" drug, compared to a "negative/resistant" drug (4).

Profiles from DNA and RNA expression analysis can help define patients at risk for early recurrence. Cell Culture Assays with "functional profiling" have a role in eliminating ineffective agents and avoid unnecessary toxicity and in directing "correct" therapy.

An ASCO tech review of drug sensitivity and resistance assays, concluded that the use of these assays for selection of chemotherapeutic agents for individual patients is not recommended outside the clinical trial setting (5).

However, Medicare contractor National Heritage Insurance Company spent six months reviewing everything about the cell culture assay, read all of ASCO arguments, and upon reviewing all available information, made the decision to reverse trend and go on record as formally approving the service and providing coverage.

They found that even back in 1999, the Medicare Advisory Panel concluded that cell culture assays tests offered clinical utility. After listening to detailed clinical evidence, the Medicare Coverage Advisory Committee found that these assay systems can aid physicians in deciding which chemotherapies work best in battling an individual patient's form of cancer (6).

Although Medicare had been reimbursing for cell culture drug "resistance" tests since 2000, it wasn't until the beginning of this year that they abandoned the artificial distinction between "resistance" testing and "sensitivity" testing and are providing coverage for the whole FDA-approved kit. The decision had been made that the assay is a perfectly appropriate medical service, worthy of coverage on a non-investigational basis (7).

References

1. J Thorac Cardiovasc Surg 2007;133:352-363. Chemotherapy Resistance and Oncogene Expression in NSCLC. http://jtcs.ctsnetjournals.org/cgi/content/abstract/133/2/352

2. J Clin Onco, 2006 ASCO Annual Meeting Proceedings Part 1. Vol 24, No. 18S (June 20 Supplement), 2006: 17117. Genfitinib-induced cell death in short term fresh tumor cultures predicts for long term patient survival in previously-treated NSCLC. Link

3. Eur J Clin Invest, Volume 37(suppl. 1):60, April 2007. Functional profiling with cell culture-based assays for kinase inhibitors and anti-angiogenic agents. http://weisenthal.org/Weisenthal_ESCIa.pdf

4. Weisenthal Cancer Group, Huntington Beach, CA and Departments of Clinical Pharmacology and Oncology, Uppsala University, Uppsala, Sweden. Current Status of Cell Culture Drug Resistance Testing (CCDRT) May, 2002. http://weisenthal.org/ccdrtrev.pdf

5. Journal of Clinical Oncology Reviews on Chemotherapy Sensitivity and Resistance Assays, September1,2004. http://weisenthal.org/jco_response.htm

6. Verbatim Transcript of Medicare Coverage Advisory Committee (MCAC) Meeting, November 15-16, 1999. http://weisenthal.org/hcfa_1.htm http://weisenthal.org/hcfa_2.htm http://weisenthal.org/hcfa_3.htm

7. Centers for Medicare & Medicaid Services http://www.medicarenhic.com/cal_prov/articles/chemoassaytest_0107.htm
http://www.highmarkmedicareservices.com/bulletins/partb/news06132007.html

Source: 
Human Tumor Assay Journal
Author/Speaker/Performer: 
Gregory D. Pawelski
Rustifox's picture

THYCA Complimentary Low Iodine Cookbook

Type: 
Article
Description: 

An excellent low iodine cookbook, complete with basic guidelines, for those with thyroid cancer who will be undergoing radioactive iodine treatment.

The "LID" - low iodine diet - deprives your body of iodine, and is normally done for a period of 2 weeks prior, and 24-48 hours following radioactive iodine treatment doses. It is important to carefully adhere to the diet particularly for the 7 days prior to treatment.

The resulting low iodine dietary content ensures your body 'soaks up' as much of the radioactive iodine treatment as possible, in all 'thyroid like' tissues, including cancerous ones.

This free resource is yet another valuable contribution to us, provided by the folks at THYCA, located at www.thyca.org

Source: 
Low Iodine Diet
Contact information: 
phone: See www.thyca.org
Author/Speaker/Performer: 
Variety of approved sources - see document
gdpawel's picture

Selling cancer chemotherapy with concessions creates conflicts of interest for oncologists

Type: 
Article
Description: 

Some Oncologists Look for New Ways To Profit From Cancer Treatments, according to a New York Times article. They examined how limits placed on profits that physicians can make on cancer drugs have left some oncologists "searching for new income," such as by "performing additional treatments that" have "the best reimbursements, whether or not the treatments" benefit the patients. Medicare until 2005 paid a markup of 20% to 100% for many cancer drugs, along with injectable treatments for arthritis and other diseases.

In 2005, Congress changed the reimbursement system to pay physicians 6% more than the average price for a given treatment. The reduction in reimbursements "did not reduce overall federal spending on cancer care," which has increased slightly in the last two years, and the difference in spending "mostly represented profit that doctors had made on the drugs," the Times reports. However, cancer doctors say the "change did nothing to reduce a larger problem in cancer treatment," according to the Times.

The decrease in payments has made it difficult for smaller practices to break even on cancer drug purchases because the practices often do not buy enough of any drug to receive rebates or discounts from drug manufacturers. Some oncologists have attempted to increase profits by "performing chemotherapy more often or installing multimillion-dollar imaging machines where they profit when their patients receive diagnostic scans" and by "putting new pressure on cancer patients to make out-of-pocket drug copayments," according to the Times.

The situation "offers a vivid example of how difficult it may be to rein in the nation's runaway health care spending without fundamentally changing the way doctors are paid," the Times reports. Robert Geller, a former oncologist and senior medical director at Alexion Pharmaceuticals, said oncologists likely will continue to find ways to profit from Medicare as long as they are paid by procedure and not for time spent with patients.

In related news, the Times examines how before the change to Medicare reimbursements for cancer treatments, pharmaceutical companies "sometimes calculated to the penny the profits that doctors could make from their drugs" and sales representatives from the companies "shared those profit estimates with doctors and their staffs," according to industry do***ents that have become public in a federal civil lawsuit against drug makers. The lawsuit, filed by cancer patients and health insurers, alleges that marketing practices of drug companies caused them to be overcharged for oncology medicines because list prices for the drugs were higher than the actual cost of the drugs for physicians.

Source: 
Healthy Skepticism
Author/Speaker/Performer: 
Gregory D. Pawelski

Ease Patients' Suffering with Access to Medical Marijuana: A Cancer Survivor's Story

Type: 
Article
Description: 

Connecticut’s Compassionate Use medical marijuana bill will be heard in its next committee tomorrow–Tuesday. So, we need to keep the same momentum going that pushed this through the General Law Committee like last week for the Public Health Committee for tomorrow’s hearing!

A phone call can also make a big impression on legislators. You can call the Public Health Committee before 9 a.m. on Tuesday to express your support for HB 6715. The number is 860-240-0560.

For more info on the bill, here’s a piece that I worked with the Drug Policy Alliance on, advocating for the passage of the CT’s Compassionate Use Bill on Huffington Post today.
http://www.huffingtonpost.com/cole-krawitz/ease-patients-suffering-_b_47309.html

You can also take action here:

http://actioncenter.drugpolicy.org/action/index.asp?step=2&item=31732&MS=CTmmj043007-ip

Source: 
Huffington Post
Author/Speaker/Performer: 
Cole Krawitz
gdpawel's picture

Medicare Contractor Establishes Reimbursement Coverage Policy for Cell Culture Assay Tests

Type: 
Article
Description: 

National Heritage Insurance Company (NHIC), the contractor that administers Medicare programs in California, has established a positive coverage policy for Cell Culture Assay Tests known as Chemosensitivity (Resistance) Testing or Oncologic In Vitro Chemoresponse Assays for a tumor specimen from a Medicare patient obtained anywhere within the United States, but submitted for testing by one of the approved laboratories located within Southern California. Medicare bills for this testing are billed through NHIC because the test is conducted by the approved laboratories in California.

This pre-test can help see what treatments have the best opportunity of being successful for "high" risk cancer patients. The test measures the response of "live" tumor cells to drug exposure. Following this exposure, the assays measure both cell metabolism and cell morphology (Functional Profiling). The integrated effect of the drugs on the whole cell, resulting in a cellular response to the drug, measuring the interaction of the entire genome. Assays based on "cell-death" occur in the entire population of tumor cells.

This cell culture assay technology has been clinically validated for the selection of optimal chemotherapy regimens for individual patients. It is a laboratory analysis based on tumor tissue profiling that uses "fresh" human tumor biopsy or surgical specimen to determine which drugs or combinations of chemotherapeutic agents have the highest likelihood of response for individual cancer patients.

Following the collection of "fresh" tumor cells obtained from surgery or tru-cut needle biopsies, a cell culture assay is performed on the tumor sample to measure drug activity (sensitivity and resistance). This will pinpoint which drug(s) are most effective. Tissue, blood, bone marrow, and ascites and pleural effusions are possibilities, providing tumor cells are present. At least one gram of fresh tissue is needed to perform the tests, and a special kit is obtained in advance from the lab. The treatment program developed through this approach is known as assay-directed therapy.

Individualized assay-directed therapy is based on the premise that each patient's cancer cells are unique and therefore will respond differently to a given treatment. This is in stark contrast to standard or empiric therapy, which chemotherapy for a specific patient is based on average population studies from prior clinical trials.

The decision had been made that the assay is a perfectly appropriate medical service, worthy of coverage on a non-investigational basis. What is of particular significance is that they abandoned the artificial distinction between "resistance" testing and "sensitivity" testing and are providing coverage for the whole FDA-approved kit. Drug "sensitivity" testing is merely a point a little farther along on the very same continuum which "resistance" testing resides.

Cell cuture assay tests based on "cell-death" have proven very effective in identifying novel treatment combinations for a variety of cancers. The value of cell-death assays is that they can and do accurately predict clinical outcomes and define novel chemotherapeutic synergies. It can help see what treatments will not have the best opportunity of being successful (resistant) and identify drugs that have the best opportunity of being successful (sensitive).

The current clinical applications of in vitro chemosensitivity testing is ever more important with the influx of new "targeted" therapies. Given the technical and conceptual advantages of "functional profiling" of cell culture assays together with their performance and the modest efficacy for therapy prediction on analysis of genome expression, there is reason for renewed interest in these assays for optimized use of medical treatment of malignant disease.

The payment provided will be sufficiently realistic that all Medicare patients for whom this testing is indicated will be able to get it with only the routine 20% co-payment, as Medi-gap insurance secondaries are mandated to provide payment for co-pays for Medicare-approved services.

The coverage became effective for claims for services performed on or after February 19, 2007. The decision is posted at:

http://www.medicarenhic.com/cal_prov/articles/chemoassaytest_0107.htm

NHIC Medicare Services reimburses qualified laboratories in Southern California for cell culture assay tests on a Medicare patient anywhere in the United States.

Likewise, Highmark Medicare Services reimburses a qualified laboratory in Pennsylvania for cell culture assay tests on a Medicare patient anywhere in the United States.

NHIC has jurisdiction over Southern California, so that is who gets billed when the laboratory is located in California.

Highmark has jurisdiction over laboratories in Pennsylvania, so that is who gets billed when the laboratory is located in Pennsylvania.

The coverage decision is posted at:

http://www.highmarkmedicareservices.com/bulletins/partb/news06132007.html

Source: 
Human Tumor Assay Journal
Author/Speaker/Performer: 
Gregory D. Pawelski
BlondeJob's picture

Management of recurrent or progressive high grade astrocytoma and anaplastic oligodendroglioma

Type: 
Article
Description: 

Outline of Topic

INTRODUCTION

BENEFIT OF SALVAGE THERAPY

SURGERY
• Gliadel wafer

RADIATION THERAPY
• Brachytherapy
• Stereotactic radiosurgery
• Stereotactic radiotherapy
• Concurrent chemotherapy

CHEMOTHERAPY
• General principles
• The blood brain barrier
• Clinical trial design
• Defining treatment activity in phase II trials
• Phase III testing
• Evaluation of QOL during treatment
• Analysis of phase III trial outcomes
• Single agent chemotherapy
• Temozolomide
• Combination chemotherapy
• Antiangiogenic agents
• Anaplastic oligodendroglioma

SUMMARY AND RECOMMENDATIONS

Source: 
Up to Date Patient Information
Author/Speaker/Performer: 
Tracy Batche, M, MPH
BlondeJob's picture

Perfect Love Cast Out Fear

Type: 
Article
Description: 

by Joyce Meyer
There is no fear, in love [dread does not exist], but full-grown (complete, Perfect) love turns fear out of doors and expels every trace of terror! For fear brings with it the thought of punishment, and [so] he who is afraid has not reached the full maturity of love [is not yet grown into Love's complete perfection]. 1 John 4:18
In years past, when I read this scripture, I misunderstood its meaning. I thought it was saying that if I could reach the place where I walked in perfect love towards other people, I would no longer experience fear in my own life. I diligently tried to love others, but it seemed like I always fail. I could not even love them imperfectly, let alone perfectly!
I had a lot of fear in my life fear that manifested in insecurity and mental torment of every kind. A person, who is fearful, worries. He is anxious about many things. The past, the future, finances, what people think, etc., these are his constant companions, which literally bring torment. The King James version of I John 4:18 certainly describes fear accurately when it says that, "fear hath torment."
There are many evil spirits that Satan uses to make people miserable, but I personally believe that fear is the master spirit. Fear seems to be the root of most of the problems that steal our peace. For example, if we find ourselves uncomfortable in a group of people, it is usually because we fear what they think of us. If we are trying to control a situation and it is causing us to get into strife, it is often because we are afraid that we will be taken advantage of, if we don't control everything.
THE CONTROL ISSUE
Trying to control people, cir***stances, and even God is a hard task. As a matter of fact, it is impossible. Out of fear, I spent many years trying to control everything and everyone. I was fearful of being hurt or taken advantage of, as I had been in the past. I had not yet learned about "perfect love that casts out fear." I was busy being in charge of everything being the great choir director of my life. The Holy Spirit wants to guide, direct, and control us. If we allow Him, He will direct us into great blessings for our lives. We are to operate in self-control and give the Holy Spirit control of our lives, but we should never try to control other people. Satan uses manipulation and control to get his way, but these are not the methods that God's children should use to get what they desire.
We are to trust God, pray about what we want, and believe that He will do the best for us at the right time. This is difficult to learn because all too often our experience with people teaches us not to trust. We must learn that people and God are not alike. All people are imperfect and even those who try not to hurt others, occasionally do. How can imperfect people love us with perfect love? If they could, we would have no fear. Our fears concerning people being hurt and disappointed by them, would be ended.
Because the emotional pain of rejection, judgment, betrayal, criticism, etc. is very real and devastating, we naturally avoid it once we have experienced it. It seems that people fall into one of two categories, they either withdraw in fear and live lonely lives where they avoid close relationships, or they do what I once did. They want to have relationships, but they can never really develop proper ones because of all their fears.
They end up controlling, manipulating, and being angry a lot. In general, their lives are frustrating, because much of the time, they truly don't know what is wrong. They are reacting out of old wounds rather than acting on the truth of God's Word.
THE CURE FOR THE INSECURE
Insecurity is said to be an epidemic in today's society. There are so many insecure people trying to have relationships with other insecure people. We find a very high percentage of this kind of relationships, which the world calls dysfunctional. This simply means they are not functioning properly.
Most people are raised in dysfunctional homes. They go out into society and continue the dysfunction, and each generation adds to the last one's problems until society becomes increasingly more dysfunctional. There is, however, an answer. His name is Jesus Christ.
When Jesus said in John 14:6, ...I am the Way..., He not only meant that He was the Way to the Father and the Way to heaven, but I believe He also meant that He was the Way out of every wrong and messed-up situation.
If invited, Jesus can get into the middle of dysfunctional lives and make them functional again. He restores, renews, redeems, reconciles, and refreshes. Jesus is "re" everything. The prefix "re" means "to go back again, or to return to the starting place". Our heavenly Father, through Jesus Christ, intends to get us back to the place, where Satan messed things up, and to give us a new beginning.
If we repent, He removes the reproach of the past, gives us a full recompense for our past hurts. Yes, Jesus is the only Way.
Why should Jesus help us in this manner? He does it because He is love because He loves us. He is God's love gift to us. Jesus is the manifestation of Perfect Love. Only Perfect Love can cast out fear. One thing, we need to concentrate on and seek God for, is a revelation about the love He has extended towards us.
Very few people have a deep and abiding revelation concerning the love of God. I believe God wants me to tell you that He loves you very much. That may sound simple, but it is the most powerful thing you can believe. When we know (without doubt) the perfect, complete love that God has for us, it will cause fear to lose its grip on our lives.
LEARNING TO ABIDE IN HIS LOVE
The word, abide means "to dwell in or live". It does not refer to "visiting". It refers to staying or remaining. I don't visit my house; I live in it. We should learn to live in the love of God. I John 4:16 in the Amplified translation brings out the point that we should become conscious and aware of the love God has for us. The knowledge of His love should not be some biblical fact to which we mentally assent, but it should be a daily living reality in our lives. This scripture says we should observe it and experience it.
And we know (understand, recognize, are conscious of, by observation and by experience) and believe (adhere to and put faith in and rely on) the love God cherishes for us. God is love, and he who dwells and continues in God, God dwells and continues in him. (I John 4:16)
I was so desperate for a revelation concerning the love of God, that several years ago I began to keep a journal of the things He did in my life that I believed to be a display of His love. No matter how small they were, I recorded them. This process helped me to become more conscious of His love. I needed to dwell in God's love because I needed a lot of healing. I was insecure and fearful, and I have found out that the love of God is the cure for the insecure.
When people gave me things, I recorded it. When I was shown favor in situations, I recorded it. When God answered prayers and did things for me that I had requested, I recorded it. Many of the things I recorded seemed rather childish, but they were helping me become like the little child Jesus said we should be a child who is trusting, humble, lowly, and loving.
I believe God is showing His love for us daily in many different ways, but because we have not trained ourselves to be "conscious of His love," we miss what He is doing. His love is there, but it is not a reality to us. Therefore, it does not benefit us, as it should.
Paul's prayer for the church, as recorded in the book of Ephesians, indicates how very important it is that we have a deep revelation concerning how much God loves us. Paul could have prayed for anything. He could have prayed for them to have power, to do miracles, to exercise authority over the devil. But Paul prayed for the church to be rooted deeply in God's love.
Paul knew that was the starting point the place from which every point starts the place from which everything else grows. Power, miracles, victory, authority are all based on our being secure in the fact that God loves us.
May Christ through your faith [actually] dwell (settle down, abide, make His permanent home) in your hearts! May you be rooted deep in love and founded securely on love, that you may have the power and be strong to apprehend and grasp with all the saints [God's devoted people, the experience of that love] what is the breadth and length and height and depth [of it]; [that you may really come] to know [practically, through experience for yourselves] the love of Christ, which far surpasses mere knowledge [without experience]; that you may be filled [through all your being] unto all the fullness of God [may have the richest measure of the divine Presence, and become a body wholly filled and flooded with God Himself]! Ephesians 3:17-19
These scriptures make it clear that we need to experience His love not just have head knowledge, but a deep revelation, and that the roots of our being should be "securely" planted in His love.
THE FEAR OF LACK
There are endless varieties of fear, but one of the tormenting fears that many people suffer from is the fear of lack. They fear that their needs will not be met that God will not come through in time.
Hebrews 13:5-6 gives great comfort to those in this situation. Let your character or moral disposition be free from love of money [including greed, avarice, lust, and craving for earthly possessions] and be satisfied with your present [cir***stances and with what you have]; for He [God] Himself has said, I will not in any way fail you nor give up nor leave you without support. [I will] not, [I will] not, [I will] not in any degree leave you helpless nor forsake nor let [you] down (relax My hold on you [Assuredly not!]
So we take comfort and are encouraged and confidently and boldly say, The Lord is my Helper; I will not be seized with alarm [I will not fear or dread or be terrified]. What can man do to me?
You may be in a situation right now that you have never been in before. You may be facing new responsibility that you don't know how to handle. You may have needs that are beyond your resources, and the spirit of fear is attacking you and telling you that you are not going to make it. You may feel all alone in your situation, like nobody cares, but God cares about you!
When God says in these scriptures to be satisfied with your present cir***stances, He does not mean that you cannot desire change. But we should be content in Jesus, knowing that He has heard our prayers and believing that He will never fail us. We must learn how to enjoy where we are on the way to where we are going.
God is a God of progress. He is never standing still. Even when it seems to us that absolutely nothing is happening in our lives, God is working behind the scene on things that He will manifest at exactly the right time. God is Life and life must flow, otherwise it is no longer life. Dead things stagnate and no longer move, but life is always moving, stirring, making progress.
Beloved, God has a good plan for you, and He will manifest it right on time. Fear not, God is with you and He will never leave you nor forsake you. He will not leave you without support! If you need financial support, He will provide. If it is physical support you need, He will sustain you while you are waiting for your full manifestation of healing. If you need emotional support, He will comfort you with the kind of comfort that only the Holy Spirit can give. He will nourish you and bring you back to a place of strength in every area of your life. God is for you. He is not against you. Satan is against you, but God is for you. The greater One lives in you!
LET NOTHING SEPARATE YOU FROM GOD'S LOVE
Romans 8:35-39 speaks to us about difficult times and how important it is not to allow them to separate us from God's love. I have discovered over the years that His love sustains me in times of great trial and stress. During hard times, Satan works overtime trying to convince us that God does not love us that if He did, either we would not be in this situation, or He would have delivered us by now.
I affirm out loud from my own mouth the truth that God does love me during these attacks of fear. I encourage you to say several times a day with authority, "God loves me!" Don't allow the devil to steal this truth from you.
Ephesians 6 speaks of wearing spiritual armor during demonic attacks. One piece of that armor is the belt of truth. The Amplified Bible states that we are to tighten the belt of truth during attack. That means the truths we have learned from God's Word must be held onto tightly during trials.
Let me close with these scriptures from Romans 8:35-39 and I pray that they will comfort you right now; Who shall ever separate us from Christ's love? Shall suffering and affliction and tribulation? Or calamity and distress? Or persecution or hunger or destitution or peril or sword?
Even as it is written, For Thy sake we are put to death all the day long; we are regarded and counted as sheep for the slaughter. Yet amid all these things we are more than conquerors and gain a surpassing victory through Him Who loved us.
For I am persuaded beyond doubt (am sure) that neither death nor life, nor angels nor principalities, nor things impending and threatening nor things to come, nor powers, nor height nor depth, nor anything else in all creation will be able to separate us from the love of God which is in Christ Jesus our Lord.
As long as you refuse to let anything separate you from God's love, you will have the victory.

Source: 
Enjoying Everyday Life
Contact information: 
phone: I don't see a number
Author/Speaker/Performer: 
Joyce Meyer
oldgrumny's picture

Today My Life

Type: 
Article
Description: 

You always know that the day will come that your life may be coming to end. For some it comes early, for some in mid life and hopefully for the rest of us when we are old and gray.
During the road of life we take risks, we do dumb things and we make choices because we think we are fearless, a superman of sorts and you only die when you are old. We spend much of our lives in the early years chasing the girls, then getting married and having a family, then years cultivating our careers so we can have the lifestyle that we have always dreamed of and along the way we forget about ourselves and the choices we made not to mention the damage these choices can do to you later in life. They say when you have a life changing situation the best thing is to write it down because you may want to share it with others so here we go.

Over and over we hear and read about all the bad things that can happen to us from alcohol, drugs and smoking. Do we listen? We all know the answer to that for we continue to do bad things to our body. I am just as guilty because I didn

Source: 
Today My Life
Author/Speaker/Performer: 
Paul Haller

Pages